Compare Adaptive Biotechnologies Corp (ADPT) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bank of Nova Scotia — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Bank of Nova Scotia trades at $84.92 (market cap $105.63B). The key difference: Bank of Nova Scotia is far larger — about 31.7× Adaptive Biotechnologies Corp's market cap, and Bank of Nova Scotia pays a 3.83% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BNS | |
|---|---|---|
Market Cap | $3.33B | $105.63B |
Sector | Health | Financials |
52-Week High | $22.37 | $87.35 |
52-Week Low | $10.24 | $54.50 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BNS trades at $86.20, up 0.94% today, with strong technical momentum showing bullish moving averages and resistance near $88. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS expected at $1.51, while revenue grew to $37.10B in 2025. Recent news highlights dividend increases and strategic acquisitions like MapleMark Bank, reinforcing growth prospects in global markets.
Outlook remains positive with analyst consensus favoring Buy ratings (52.63%), though valuation multiples like P/E of 17.05 warrant monitoring. Key risks include economic sensitivity and debt levels, but robust cash flow and dividend yield support income-focused investors. Upside depends on execution of growth initiatives and sustained earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
